Comprehensive Stock Comparison
Compare Evogene Ltd. (EVGN) vs Azitra, Inc. (AZTR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  EVGN | 50.9% revenue growth vs AZTR's -100.0% |
| Stability / Safety | EVGN | Beta 0.54 vs AZTR's 0.65 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | EVGN | -37.3% vs AZTR's -92.4% |
| Efficiency (ROA) |  AZTR | -0.2% ROA vs EVGN's -10.5%, ROIC -0.8% vs -102.4% |
Who Each Stock Is For
Income & stability
EVGNbeta 0.54
Growth exposure
EVGNRev growth 50.9%, EPS growth 44.7%, 3Y rev CAGR 109.2%
Long-term compounding (10Y)
EVGN-98.9% 10Y total return vs AZTR's -100.0%
Sleep-well-at-night portfolio
EVGNLower volatility, beta 0.54, Low D/E 86.8%, current ratio 1.15x
Defensive / Recession hedge
EVGNBeta 0.54, current ratio 1.15x
Business Model
What each company does and how it makes money
Evogene is a computational biology company that uses its proprietary AI-powered platform to discover and develop products across agriculture, human health, and industrial applications. It generates revenue through research collaborations, licensing agreements, and milestone payments from partners—primarily in agriculture (~70% of focus) and human health (~30%). The company's key advantage is its Computational Predictive Biology platform, which leverages big data and machine learning to accelerate product discovery in life sciences with higher precision than traditional methods.
Azitra is a preclinical biopharmaceutical company developing engineered bacterial therapies for rare and serious skin diseases. It aims to generate revenue through drug development partnerships and future product sales — though currently in preclinical stages without commercial revenue. The company's key advantage lies in its proprietary platform for engineering commensal skin bacteria to deliver therapeutic proteins directly to diseased skin.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EVGN 3AZTR 1EVGN1/1 metricsAZTR6/9 metricsEVGN6/6 metricsEVGN2/2 metricsEVGN leads in 3 of 6 categories (Financial Metrics, Total Returns). AZTR leads in 1 (Profitability & Efficiency). 1 tied.
Financial Metrics (TTM)
EVGN and AZTR operate at a comparable scale, with $5M and $0 in trailing revenue.
| Metric | EVGNEvogene Ltd. | AZTRAzitra, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $5M | $0 |
| EBITDAEarnings before interest/tax | -$13M | -$11M |
| Net IncomeAfter-tax profit | -$3M | -$11M |
| Free Cash FlowCash after capex | -$17M | -$86M |
| Gross MarginGross profit ÷ Revenue | +16.1% | — |
| Operating MarginEBIT ÷ Revenue | -2.8% | — |
| Net MarginNet income ÷ Revenue | -52.3% | — |
| FCF MarginFCF ÷ Revenue | -3.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +133.6% | -6.9% |
Valuation Metrics
| Metric | EVGNEvogene Ltd. | AZTRAzitra, Inc. |
|---|---|---|
| Market CapShares × price | $7M | $2M |
| Enterprise ValueMkt cap + debt − cash | $5M | -$1.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.29x | -0.08x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.85x | — |
| Price / BookPrice ÷ Book value/share | 0.32x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AZTR delivers a -0.3% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-16 for EVGN. AZTR carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to EVGN's 0.87x. On the Piotroski fundamental quality scale (0–9), EVGN scores 3/9 vs AZTR's 1/9, reflecting mixed financial health.
| Metric | EVGNEvogene Ltd. | AZTRAzitra, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -15.9% | -0.3% |
| ROA (TTM)Return on assets | -10.5% | -0.2% |
| ROICReturn on invested capital | -102.4% | -0.8% |
| ROCEReturn on capital employed | -66.5% | -0.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | 0.87x | 0.11x |
| Net DebtTotal debt minus cash | -$2M | -$1.6B |
| Cash & Equiv.Liquid assets | $15M | $2.1B |
| Total DebtShort + long-term debt | $13M | $422M |
| Interest CoverageEBIT ÷ Interest expense | -4.42x | -13.79x |
Total Returns (with DRIP)
A $10,000 investment in EVGN five years ago would be worth $177 today (with dividends reinvested), compared to $2 for AZTR. Over the past 12 months, EVGN leads with a -37.3% total return vs AZTR's -92.4%. The 3-year compound annual growth rate (CAGR) favors EVGN at -51.9% vs AZTR's -94.4% — a key indicator of consistent wealth creation.
| Metric | EVGNEvogene Ltd. | AZTRAzitra, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -26.2% | -39.0% |
| 1-Year ReturnPast 12 months | -37.3% | -92.4% |
| 3-Year ReturnCumulative with dividends | -88.9% | -100.0% |
| 5-Year ReturnCumulative with dividends | -98.2% | -100.0% |
| 10-Year ReturnCumulative with dividends | -98.9% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -51.9% | -94.4% |
Risk & Volatility
EVGN is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than AZTR's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EVGN currently trades 34.5% from its 52-week high vs AZTR's 6.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EVGNEvogene Ltd. | AZTRAzitra, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.65x |
| 52-Week HighHighest price in past year | $2.42 | $2.66 |
| 52-Week LowLowest price in past year | $0.81 | $0.16 |
| % of 52W HighCurrent price vs 52-week peak | +34.5% | +6.4% |
| RSI (14)Momentum oscillator 0–100 | 38.7 | 32.6 |
| Avg Volume (50D)Average daily shares traded | 551K | 1.3M |
Analyst Outlook
| Metric | EVGNEvogene Ltd. | AZTRAzitra, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 23 | Mar 26 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | 100 | 7.19 | -92.8% |
| Azitra, Inc. (AZTR) | 81.17 | 0.02 | -100.0% |
Evogene Ltd. (EVGN) returned -98% over 5 years vs Azitra, Inc. (AZTR)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | $7M | $9M | +30.1% |
| Azitra, Inc. (AZTR) | $110000.00 | $0.00 | -100.0% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | -154.7% | -193.7% | -25.2% |
| Azitra, Inc. (AZTR) | -81.3% | -119.6% | -47.1% |
Evogene Ltd.'s net margin went from -155% (2015) to -194% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | -0.77 | -2.89 | -275.3% |
| Azitra, Inc. (AZTR) | -3.33 | -2.25 | +32.5% |
Chart 5Free Cash Flow — 5 Years
Evogene Ltd. generated $-20M FCF in 2024 (+20% vs 2021). Azitra, Inc. generated $-11B FCF in 2025 (-128900% vs 2021).
EVGN vs AZTR: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — EVGN or AZTR?
Over the past 5 years, Evogene Ltd. (EVGN) delivered a total return of -98.2%, compared to -100.0% for Azitra, Inc. (AZTR). A $10,000 investment in EVGN five years ago would be worth approximately $177 today (assuming dividends reinvested). Over 10 years, the gap is even starker: EVGN returned -98.9% versus AZTR's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — EVGN or AZTR?
By beta (market sensitivity over 5 years), Evogene Ltd. (EVGN) is the lower-risk stock at 0.54β versus Azitra, Inc.'s 0.65β — meaning AZTR is approximately 19% more volatile than EVGN relative to the S&P 500. On balance sheet safety, Azitra, Inc. (AZTR) carries a lower debt/equity ratio of 11% versus 87% for Evogene Ltd. — giving it more financial flexibility in a downturn.
03Which has better profit margins — EVGN or AZTR?
Azitra, Inc. (AZTR) is the more profitable company, earning 0.0% net margin versus -193.7% for Evogene Ltd. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTR leads at 0.0% versus -255.4% for EVGN. At the gross margin level — before operating expenses — EVGN leads at 39.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — EVGN or AZTR?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is EVGN or AZTR better for a retirement portfolio?
For long-horizon retirement investors, Evogene Ltd. (EVGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.54)). Both have compounded well over 10 years (EVGN: -98.9%, AZTR: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between EVGN and AZTR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.